2666 篇
1099 篇
195081 篇
3393 篇
6327 篇
2249 篇
2814 篇
539 篇
29826 篇
10152 篇
3200 篇
773 篇
2312 篇
1328 篇
451 篇
753 篇
1391 篇
2638 篇
2749 篇
4077 篇
生物制品行业:疫苗行业系列报告之批签发跟踪-疫苗4月批签发数据专题(20200513)
2020 年4 月,中检所共批签发疫苗5,479.40 万瓶,同比增长37.36%,环比增长20.01%。2020 年1-4 月,累计批签发疫苗18,696 万瓶,同比增长26.71%。
一、疫苗总体批签发量5,479 万瓶,单月同比增长37% ....................................................... 5
二、重点品种 ......................................................................................................................... 5
1. 肺炎疫苗 ........................................................................................................................ 5
1.1 13 价肺炎球菌多糖结合疫苗 ................................................................................... 5
1.2 23 价肺炎球菌多糖疫苗 ........................................................................................... 6
2. 人乳头瘤病毒疫苗(HPV) .......................................................................................... 7
3. 轮状病毒疫苗 ................................................................................................................ 8
4. Hib 及联苗 ...................................................................................................................... 9
4.1 Hib 单苗 .................................................................................................................. 9
4.2 Hib 联苗 ................................................................................................................ 10
5. 流感裂解疫苗 ............................................................................................................... 11
6. 乙肝疫苗 ....................................................................................................................... 11
7. 水痘疫苗 ...................................................................................................................... 12
三、重点公司 ....................................................................................................................... 13
1.重点公司2020 年1-4 月疫苗批签发跟踪 ...................................................................... 13
2. 上市公司估值 .............................................................................................................. 14
风险提示 .............................................................................................................................. 15